Natasha K. Brockwell

Natasha K. Brockwell

Auto-generated profile, based on publicly available information

Natasha K. Brockwell

Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
NBNatasha K. Brockwell
Natasha K. Brockwell
KOKatie L. Owen
Katie L. Owen
DZDamien Zanker
Damien Zanker
ASAlex Spurling
Alex Spurling
JRJai Rautela
Jai Rautela
BPBelinda S Parker
Belinda S Parker
The lack of targeted therapies available for triple-negative breast cancer (TNBC) patients who fail to respond to first-line chemotherapy has sparked interest in immunotherapeutic approaches. However, trials utilizing checkpoint inhibitors targeting the PD-1/PD-L1 axis in TNBC have had underwhelming responses. Here, we investigated the interplay between type I IFN signaling and the PD-1/PD-L1 axis and tested the impact of combining IFN inducers, as immune activators, with anti–PD-1, to induce an antimetastatic immune response. Using models of TNBC, we demonstrated an interplay between type I IFN signaling and tumor cell PD-L1 expression that affected therapeutic response. The data revealed that the type I IFN-inducer poly(I:C) was an effective immune activator and antimetastatic agent, functioning better than anti–PD-1, which was ineffective as a single agent. Poly(I:C) treatment induced PD-L1 expression on TNBC cells, and combined poly(I:C) and anti–PD-1 treatment prolonged metastasis-free survival in a neoadjuvant setting via the induction of a tumor-specific T-cell response. Use of this combination in a late treatment setting did not impact metastasis-free survival, indicating that timing was critical for immunotherapeutic benefit. Together, these data demonstrated anti–PD-1 as an ineffective single agent in preclinical models of TNBC. However, type I IFN inducers were effective immune activators, and neoadjuvant trials combining them with anti–PD-1 to induce a sustained antitumor immune response are warranted. Cancer Immunol Res; 5(10); 871–84. ©2017 AACR.

31 October 2017 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
HDHendrika M Duivenvoorden
Hendrika M Duivenvoorden
JRJai Rautela
Jai Rautela
LELaura Edgington-Mitchell
Laura Edgington-Mitchell
ASAlex Spurling
Alex Spurling
DGDavid Greening
David Greening
BPBelinda S Parker
Belinda S Parker

29 August 2019 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
NBNatasha K. Brockwell
Natasha K. Brockwell
JRJai Rautela
Jai Rautela
KOKatie L. Owen
Katie L. Owen
LGLinden J. Gearing
Linden J. Gearing
SDSiddhartha Deb
Siddhartha Deb
BPBelinda S Parker
Belinda S Parker
Patients diagnosed with triple negative breast cancer (TNBC) have an increased risk of rapid metastasis compared to other subtypes. Predicting long-term survival post-chemotherapy in patients with TNBC is difficult, yet enhanced infiltration of tumor infiltrating lymphocytes (TILs) has been associated with therapeutic response and reduced risk of metastatic relapse. Immune biomarkers that predict the immune state of a tumor and risk of metastatic relapse pre- or mid-neoadjuvant chemotherapy are urgently needed to allow earlier implementation of alternate therapies that may reduce TNBC patient mortality. Utilizing a neoadjuvant chemotherapy trial where TNBC patients had sequential biopsies taken, we demonstrate that measurement of T-cell subsets and effector function, specifically CD45RO expression, throughout chemotherapy predicts risk of metastatic relapse. Furthermore, we identified the tumor inherent interferon regulatory factor IRF9 as a marker of active intratumoral type I and II interferon (IFN) signaling and reduced risk of distant relapse. Functional implications of tumor intrinsic IFN signaling were demonstrated using an immunocompetent mouse model of TNBC, where enhanced type I IFN signaling increased anti-tumor immunity and metastasis-free survival post-chemotherapy. Using two independent adjuvant cohorts we were able to validate loss of IRF9 as a poor prognostic biomarker pre-chemotherapy. Thus, IRF9 expression may offer early insight into TNBC patient prognosis and tumor heat, allowing for identification of patients that are unlikely to respond to chemotherapy alone and could benefit from further immune-based therapeutic intervention.

1 June 2019 in Cytokine
Verified
Journal Article
Closed access
NBNatasha K. Brockwell
Natasha K. Brockwell
BPBelinda S Parker
Belinda S Parker